A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

Recruitment Status
ACTIVE, NOT RECRUITING
(See Contacts and Locations)Verified March 2026 by Janssen Research & Development, LLC
Sponsor
Janssen Research & Development, LLC
Information Provided by (Responsible Party)
Janssen Research & Development, LLC
Clinicaltrials.gov Identifier
NCT06934226
Other Study ID Numbers:
77242113PSO3006
First Submitted
April 10, 2025
First Posted
April 17, 2025
Last Update Posted
April 12, 2026
Last Verified
March 2026

ClinicalTrials.gov processed this data on April 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Plaque Psoriasis
Drug: JNJ-77242113Drug: JNJ-77242113Drug: JNJ-77242113

Study Design

Study TypeInterventional
Actual Enrollment752 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Study Start DateApril 14, 2025
Actual Primary Completion DateNovember 16, 2025
Actual Study Completion Date1yr 3mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
Arm 1: JNJ 77242113
Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.
Arm 2: Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.
Arm 3: Ustekinumab
Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.

Outcome Measures

Primary Outcome Measures
  1. JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
    IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  2. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
Secondary Outcome Measures
  1. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.
  2. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
  3. JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
    IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  4. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
    IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  5. JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
  6. JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.
  7. JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
    PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  8. JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  9. Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
    An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product \& is medically important.
  10. JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.
  11. JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
    DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  12. JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
    DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  13. JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
    BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
  14. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  15. JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  16. JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  17. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  18. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
    PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  19. JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
    DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  20. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
    DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  21. JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
    BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.
  22. JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
    IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  23. JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.
  24. JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
    PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Eligibility Criteria

Ages Eligible for Study(Child, Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
Total investigator global assessment (IGA) \>=3 at screening and baseline
Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria
Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)

Contacts and Locations

Sponsors and CollaboratorsJanssen Research & Development, LLC
Locations
Cahaba Research Inc | Birmingham Alabama, United States, 35244California Dermatology & Clinical Research Institute | Encinitas California, United States, 92024T Joseph Raoof Md Inc | Encino California, United States, 91436First OC Dermatology | Fountain Valley California, United States, 92708Dermatologist Medical Group of North County, Inc. | Oceanside California, United States, 92056NorCal Clinical Research | Rocklin California, United States, 95765Integrative Skin Science and Research | Sacramento California, United States, 95815MedDerm Associates | San Diego California, United States, 92103Southern California Dermatology | Santa Ana California, United States, 92701Olive View-UCLA Education & Research Institute | Sylmar California, United States, 91342University of Conn Health Center | Farmington Connecticut, United States, 06030Driven Research LLC | Coral Gables Florida, United States, 33134Bioclinical Research Alliance Inc. | Miami Florida, United States, 33155Renstar Medical Research | Ocala Florida, United States, 34470Forcare Clinical Research Inc | Tampa Florida, United States, 33613Hamilton Research LLC | Alpharetta Georgia, United States, 30022Northshore Medical Group | Skokie Illinois, United States, 60076Indiana Clinical Trial Center | Plainfield Indiana, United States, 46168University of Iowa | Iowa City Iowa, United States, 52242Equity Medical | Bowling Green Kentucky, United States, 42104Tufts Medical Center | Boston Massachusetts, United States, 02111Metro Boston Clinical Partners | Brighton Massachusetts, United States, 02135The Derm Institute of West Michigan | Caledonia Michigan, United States, 49316Henry Ford Hospital | Detroit Michigan, United States, 48202Hamzavi Dermatology | Fort Gratiot Michigan, United States, 48059Somerset Skin Centre | Troy Michigan, United States, 48084Minnesota Clinical Study Center | New Brighton Minnesota, United States, 55112Cleaver Dermatology | Kirksville Missouri, United States, 63501MediSearch Clinical Trials | Saint Joseph Missouri, United States, 64506Mount Sinai Doctors Dermatology | New York New York, United States, 10028Sadick Research Group | New York New York, United States, 10075Wilmington Dermatology Center | Wilmington North Carolina, United States, 28405Optima Research | Boardman Ohio, United States, 44512Apex Dermatology Mayfield Heights | Mayfield Heights Ohio, United States, 44124Oregon Medical Research Center | Portland Oregon, United States, 97201Oregon Dermatology and Research Center | Portland Oregon, United States, 97210Clinical Research Philadelphia | Philadelphia Pennsylvania, United States, 19114UPMC Department of Dermatology | Pittsburgh Pennsylvania, United States, 15213Health Concepts | Rapid City South Dakota, United States, 57702Advanced Research Experts PLLC | Nashville Tennessee, United States, 37211Arlington Research Center, Inc. | Arlington Texas, United States, 76011Modern Research Associates PLLC | Dallas Texas, United States, 75231Center for Clinical Studies 1 | Houston Texas, United States, 77004Progressive Clinical Research | San Antonio Texas, United States, 78213Texas Dermatology and Laser Specialists | San Antonio Texas, United States, 78218Center for Clinical Studies | Webster Texas, United States, 77598Kalo Clinical Research | West Valley City Utah, United States, 84120Frontier Derm Partners CRO, LLC | Mill Creek Washington, United States, 98012Consultora Integral de Salud SRL | Barrio Gral Paz Cba Capital , Argentina, X5000Instituto Medico De Alta Complejidad (IMAC) | Buenos Aires , Argentina, B1643CROMindout Research | Buenos Aires , Argentina, C1417EYGInstituto de Neumonologia y Dermatologia | Buenos Aires , Argentina, C1425Buenos Aires Skin | CABA , Argentina, C1055AAOInvestigaciones Medicas IMOBA SRL | CABA , Argentina, C1056ABHCIPREC | CABA , Argentina, C1061AASHalitus Instituto Medico S.A. - Dermatologia y Estetica | Caba , Argentina, C1122AAFMautalen Salud e Investigacion | CABA , Argentina, C1128Hospital Italiano de Buenos Aires | CABA , Argentina, C1199ABBInstituto De Especialidades De La Salud SRL | Rosario , Argentina, S2000DBSMR Medicina Reumatologica | San Fernando , Argentina, B1646Instituto de Investigaciones Medicas Tucuman | San Miguel de Tucumán , Argentina, T4000Monash Medical Centre | Clayton , Australia, 3168Cornerstone Dermatology | Coorparoo , Australia, 4151Premier Specialists | Kogarah , Australia, 2217The Alfred Hospital | Melbourne , Australia, 3004Royal Melbourne Hospital | Melbourne , Australia, 3050ISHI dermatology | Mitcham , Australia, 3132Westmead Hospital | Westmead , Australia, 2145Veracity Clinical Research | Woolloongabba , Australia, 4102LKH Feldkirch | Feldkirch , Austria, 6800Kepler Universitatsklinikum GmbH | Linz , Austria, 4020Universtitatsklinikum St Polten | Sankt Pölten , Austria, 3100Allgemeines Krankenhaus der Stadt Wien | Vienna , Austria, 1090UZ Brussel | Brussels , Belgium, 1090AZ St. Lucas | Ghent , Belgium, 9000Ghent University Hospital | Ghent , Belgium, 9000Universitair Ziekenhuis Leuven | Leuven , Belgium, 3000Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman | Liège , Belgium, 4000Dermatologie Maldegem | Maldegem , Belgium, 9990Skincare Studio Inc Dermatology Clinical Trials | St. John's Newfoundland and Labrador, Canada, A1E 1V4CCA Medical Research Corporation | Ajax Ontario, Canada, L1S7K8SimcoDerm Medical and Surgical Dermatology Centre | Barrie Ontario, Canada, L4M 7G1Dermatrials Research | Hamilton Ontario, Canada, L8N 1Y2Lovegrove Dermatology | London Ontario, Canada, N6A 5R9Lynderm Research Inc. | Markham Ontario, Canada, L3P 1X3Alliance Clinical Trials | Waterloo Ontario, Canada, N2J 1C4Innovaderm Research Inc. | Montreal Quebec, Canada, H2X 2V1The Centre de recherche Saint-Louis | Québec Quebec, Canada, G1W 4R4Aalborg Sygehus Syd | Aalborg , Denmark, 9100Aarhus University Hospital | Aarhus , Denmark, 8200Gentofte Hospital | Hellerup , Denmark, 2900Bispebjerg Hospital | København NV , Denmark, 2400Odense University Hospital | Odense , Denmark, 5000Sjællands University hospital | Roskilde , Denmark, 4000Klinikum Augsburg | Augsburg , Germany, 86179Fachklinik Bad Bentheim | Bad Bentheim , Germany, 48455ISA - Interdisciplinary Study Association GmbH | Berlin , Germany, 10789Universitatsklinikum Bonn | Bonn , Germany, 53127Studienzentrum an der Hase GbR | Bramsche , Germany, 49565Rosenpark Research GmbH | Darmstadt , Germany, 64283Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden | Dresden , Germany, 01307Derma-Study-Center Friedrichshafen GmbH | Friedrichshafen , Germany, 88045Universitaetsklinikum Schleswig Holstein Campus Kiel | Kiel , Germany, 24105Studienzentrum Dr Schwarz Germany | Langenau , Germany, 89129Dermatologie Mahlow | Mahlow , Germany, 15831Gemeinschaftspraxis Dres. Quist | Mainz , Germany, 55128Universitaetsklinikum Muenster | Münster , Germany, 48149Hautarztpraxis | Witten , Germany, 58453Obudai Egeszsegugyi Centrum Kft | Budapest , Hungary, 1036Uno Medical Trials Ltd. | Budapest , Hungary, 1152Derma-B Kft | Debrecen , Hungary, 4031Debreceni Egyetem Klinikai Kozpont | Debrecen , Hungary, 4032Gyongyosi Bugat Pal Korhaz | Gyöngyös , Hungary, 3200Synexus Magyarorszag Kft | Gyula , Hungary, 5700Porcika Klinika - Vasarhelyi Sarkanyfu Kft. | Hódmezővásárhely , Hungary, 6800Somogy Varmegyei Kaposi Mor Oktato Korhaz | Kaposvár , Hungary, 7400Bacs-kiskun Megyei Korhaz | Kecskemét , Hungary, 6000Allergo-Derm Bakos Kft. | Szolnok , Hungary, 5000Medmare Egeszsegugyi Es Szolgaltato Bt. | Veszprém , Hungary, 8200Specderm Poznanska sp j | Bialystok , Poland, 15 375Osteo-Medic s.c A. Racewicz, J Supronik | Bialystok , Poland, 15-351Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska | Elblag , Poland, 82 300Care Clinic Sp z o o | Katowice , Poland, 40 568Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna | Krakow , Poland, 30 002Dermed Centrum Medyczne Sp z o o | Lodz , Poland, 90-265Etyka Osrodek Badan Klinicznych | Olsztyn , Poland, 10-117SOLUMED Centrum Medyczne | Poznan , Poland, 60 529Velocity Nova Sp z o o | Skierniewice , Poland, 96 100Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej | Warsaw , Poland, 02 661Klinika Ambroziak Dermatologia | Warsaw , Poland, 02 953WroMedica | Wroclaw , Poland, 51 685Centrum Medyczne Oporow | Wroclaw , Poland, 52 416Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes | Guimarães , Portugal, 4835 044Unidade Local De Saude Da Regiao De Leiria Epe | Leiria , Portugal, 2410 197Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos | Lisbon , Portugal, 1169 050Hosp. Cuf Descobertas | Lisbon , Portugal, 1998 018Ulssa Hosp. Santo Antonio | Porto , Portugal, 4099 001Hosp. Gral. Univ. Dr. Balmis | Alicante , Spain, 03010Hosp. Univ. de Cruces | Barakaldo , Spain, 48902Hosp. Clinic de Barcelona | Barcelona , Spain, 08036Hosp. Univ. San Cecilio | Granada , Spain, 18016Grupo Dermatologico Y Estetico Pedro Jaen | Madrid , Spain, 28002Hosp. Univ. de La Princesa | Madrid , Spain, 28006Hosp. Univ. 12 de Octubre | Madrid , Spain, 28041Hosp. de Manises | Manises , Spain, 46940Hosp. Clinico Univ. de Santiago | Santiago Compostela , Spain, 15706Hosp. Virgen Macarena | Seville , Spain, 41009Hosp. Ntra. Sra. de Valme | Seville , Spain, 41014Hosp. Univ. I Politecni La Fe | Valencia , Spain, 46026Hosp. de La Marina Baixa | Villajoyosa , Spain, 03570Hosp. Clinico Univ. Lozano Blesa | Zaragoza , Spain, 50009Hosp. Univ. Miguel Servet | Zaragoza , Spain, 50009Dudley Group NHS Foundation Trust | Dudley , United Kingdom, DY1 2HQLondon North West University Healthcare NHS Trust | Harrow , United Kingdom, HA1 3UJThe Queen Elizabeth Hospital NHS Foundation Trust | Kings Lynn , United Kingdom, PE30 4ETGuys and St Thomas NHS Foundation Trust | London , United Kingdom, SE1 9RTRoyal Berkshire Hospital | Reading , United Kingdom, RG1 5ANSalford Royal Hospital | Salford , United Kingdom, M6 8HDUniversity Hospital Southampton | Southampton , United Kingdom, So166ydMid Yorkshire Hospital NHS Trust- Pinderfields Hospital | Wakefield , United Kingdom, WF1 4DG